Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
The Lancet
2019
393
10167
156-167
SUMOylation inhibition overcomes proteasome inhibitor resistance in multiple myeloma.
Blood Adv
2023
7
4
469-481
Cancer, cancer treatment and aneurysmatic ascending aorta growth within a retrospective single center study.
Vasa
2023
52
1
38-45
sCD25 as an independent adverse prognostic factor in adult patients with HLH: results of a multicenter retrospective study.
Blood Adv
2023
7
5
832-844
Kinetics of Renal Function during Induction in Newly Diagnosed Multiple Myeloma: Results of Two Prospective Studies by the German Myeloma Study Group DSMM.
Cancers (Basel)
2021
13
6
Advanced Therapy Medicinal Products and the Changing Role of Academia.
Transfus Med Hemother
2022
49
3
158-162
Bispecific T-Cell Engager-Armored Chimeric Antigen Receptor T Cells Overcome Antigen Escape From EGFRvIII-Targeted Therapy For Glioblastoma
Neurosurgery
2019
66 Suppl 1
45-45
Phase 1/2a study of the IRAK4 inhibitor CA-4948 as monotherapy or in combination with azacitidine or venetoclax in patients with relapsed/refractory (R/R) acute myeloid leukemia or lyelodysplastic syndrome.
J Clin Oncol
2022
40 Suppl S
16
Osteoprogenitor SFRP1 prevents exhaustion of hematopoietic stem cells via PP2A-PR72/130-mediated regulation of p300.
Haematologica
2023
108
2
490-501